Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (TESLA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01588496
First received: February 27, 2012
Last updated: June 27, 2014
Last verified: June 2014

February 27, 2012
June 27, 2014
April 2012
January 2014   (final data collection date for primary outcome measure)
Percent change from baseline in low density lipoprotein cholesterol at week 12 for Part A and B [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Percent change from baseline in low density lipoprotein-cholesterol at week 12 for Part A and B
Percent change from baseline in low density lipoprotein cholesterol (LDL-C) at week 12 for Part A and Part B. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01588496 on ClinicalTrials.gov Archive Site
  • Change from baseline in low density lipoprotein-cholesterol at week 12 for Part A [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change from baseline in low density lipoprotein-cholesterol at week 12 for Part A
  • Percent change from baseline in non-high density lipoprotein cholesterol at week 12 for Part A [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in non-high density lipoprotein cholesterol at week 12 for Part A
  • Percent change from baseline in apolipoprotein B at week 12 for Part A [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in apolipoprotein B at week 12 for Part A
  • Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio at week 12 for Part A [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio at week 12 for Part A
  • Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio at week 12 for Part A [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio at week 12 for Part A
  • Response rate of subjects with 15% or greater reduction in low density lipoprotein-cholesterol from baseline to Week 12 for Part A [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Response rate of subjects with 15% or greater reduction in low density lipoprotein-cholesterol from baseline to Week 12 for Part A
  • Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) at week 12 for Part A [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) at week 12 for Part A
  • Mean percent change from baseline in low density lipoprotein-cholesterol at weeks 6 and 12 for Part B [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in low density lipoprotein-cholesterol at weeks 6 and 12 for Part B
  • Percent change from baseline in apolipoprotein B week 12 for Part B [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in apolipoprotein B week 12 for Part B
  • Mean percent change from baseline in Apolipoprotein B at weeks 6 and 12 for Part B [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in Apolipoprotein B at weeks 6 and 12 for Part B
  • Percent change from baseline in Lipoprotein (a) at week 12 for Part B [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in Lipoprotein (a) at week 12 for Part B
  • Mean percent change from baseline in Lipoprotein (a) at weeks 6 and 12 for Part B [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in Lipoprotein (a) at weeks 6 and 12 for Part B
  • Change from baseline in LDL-C at week 12 for Part A and Part B. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent change from baseline in non-high density lipoprotein cholesterol (non-HDL-C) at week 12 for Part A and Part B. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent change from baseline in apolipoprotein B (ApoB) at week 12 for Part A and Part B. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent change from baseline in the total cholesterol/HDL-C ratio at week 12 for Part A and Part B. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percent change from baseline in ApoB/apolipoprotein A-1 (ApoA1) ratio at week 12 for Part A and Part B. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Response rate of subjects with 15% or greater reduction in LDL-C from baseline to Week 12 (Part A only). [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in PCSK9 at week 12 for Part A and Part B. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
A 2 Part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of Evolocumab (AMG145) in Subjects With Homozygous Familial Hypercholesterolemia Part A - Open-label, Single-arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG145) in Subjects With Homozygous Familial Hypercholesterolemia Part B - Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG145) in Subjects With Homozygous Familial Hypercholesterolemia

A study to determine the safety, tolerability, and efficacy of Evolocumab (AMG145) in subjects with homozygous familial hypercholesterolemia.

Study Masking:

Part A: Open Label Part B: Double Blind

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Homozygous Familial Hypercholesterolemia
  • Biological: Evolocumab (AMG145)
    Subcutaneous Evolocumab (AMG145) Open Label
  • Biological: Evolocumab (AMG145)
    Subcutaneous Evolocumab (AMG145)
  • Other: Placebo
    Subcutaneous Placebo
  • Active Comparator: Part A: Evolocumab (AMG145)
    Subcutaneous Evolocumab (AMG145) Open Label
    Intervention: Biological: Evolocumab (AMG145)
  • Active Comparator: Part B: Evolocumab (AMG145)
    Subcutaneous Evolocumab (AMG145)
    Intervention: Biological: Evolocumab (AMG145)
  • Placebo Comparator: Part B: Placebo
    Subcutaneous Placebo
    Intervention: Other: Placebo
Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 5;128(19):2113-20. doi: 10.1161/CIRCULATIONAHA.113.004678. Epub 2013 Sep 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58
March 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females ≥ 12 to ≤ 80 years of age
  • Diagnosis of homozygous familial hypercholesterolemia
  • Stable lipid-lowering therapies for at least 4 weeks
  • LDL cholesterol ≥ 130 mg/dl (3.4 mmol/L)
  • Triglyceride ≤ 400 mg/dL (4.5 mmol/L)
  • Bodyweight of ≥ 40 kg at screening.

Exclusion Criteria:

  • LDL or plasma apheresis within 8 weeks prior to randomization
  • New York Heart Failure Association (NYHA) class III or IV or last known left ventricular ejection fraction < 30%
  • Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of randomization
  • Planned cardiac surgery or revascularization
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
Both
12 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Belgium,   Canada,   Czech Republic,   France,   Hong Kong,   Italy,   Lebanon,   Netherlands,   New Zealand,   South Africa,   Spain
 
NCT01588496
20110233
Yes
Amgen
Amgen
Not Provided
Study Director: MD Amgen
Amgen
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP